Kfh - Vallejo

Type: Teaching hospital
Where: Vallejo, CA
Medicare CCN: 050073
Received: $75,263 in 47 records, 2020 ($0 general, $75,263 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2020	Research payment	47	$75,263

By company

Company	Records	Amount	Years
Merck Sharp & Dohme LLC	46	$59,263	2020
Janssen Research & Development, LLC	1	$16,000	2020

By nature of payment

Nature	Records	Amount
Research payment	47	$75,263

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-14	Janssen Research & Development, LLC	$16,000	Research payment	Cash or cash equivalent		Prospective Study to Investigate Pseudomonas aeruginosa and Staphylococcus aureus Bacterial Load and Patient Characteris	2020
2020-11-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-11-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-11-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-11-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-08-03	Merck Sharp & Dohme LLC	$19,541	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-06-08	Merck Sharp & Dohme LLC	$21,180	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase 2 Study of the Combination of Pembrolizumab MK-3475 Plus Epacadostat INCB024360 with Platinum-based C	2020
2020-05-08	Merck Sharp & Dohme LLC	$188	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-05-08	Merck Sharp & Dohme LLC	$176	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-05-08	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-05-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-05-08	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-05-08	Merck Sharp & Dohme LLC	$13	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-11	Merck Sharp & Dohme LLC	$16,239	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-11	Merck Sharp & Dohme LLC	$409	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-11	Merck Sharp & Dohme LLC	$383	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$188	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$176	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$35	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$21	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$21	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$13	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$13	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2020
2020-02-03	Merck Sharp & Dohme LLC	$64	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg	2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Vallejo, CA, county Solano County, CA, state California; placed by its city name.

Measure	Place (city or town) Vallejo, CA	County Solano County, CA	State California
Population B01003	124,268	451,918	39,287,377
Population, 2020 census P1	126,090	453,491	39,538,223
Median age B01002	40.6	39.2	37.9
Under 18 B01001	20.0%	21.9%	22.0%
65 and over B01001	17.9%	17.4%	15.7%
Households B11001	44,798	157,512	13,548,091
Foreign born B05002	28.7%	20.8%	27.0%
Median household income B19013	$90,171	$100,401	$99,122
Median family income B19113	$103,860	$116,065	$113,346
Per capita income B19301	$42,240	$45,127	$49,513
Poverty rate B17001	12.2%	10.0%	12.0%
Unemployment rate B23025	7.4%	6.5%	6.6%
Civilian labor force B23025	63,631	220,729	20,068,466
Mean commute (minutes) B08013	34.2	31.0	28.7
Bachelor's degree or higher B15003	28.8%	28.8%	37.1%
Housing units B25001	47,084	164,693	14,644,735
Owner-occupied B25003	57.4%	63.0%	55.9%
Renters B25003	42.6%	37.0%	44.1%
Median home value B25077	$589,500	$617,700	$734,700
Median gross rent B25064	$2,073	$2,163	$2,036
White, not Hispanic B03002	20.5%	33.2%	33.8%
Black B03002	16.9%	12.3%	5.2%
Hispanic or Latino B03002	29.8%	29.6%	40.2%
Asian B03002	22.7%	15.9%	15.3%
American Indian and Alaska Native B03002	0.3%	0.2%	0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Vallejo, CA.